Results 241 to 250 of about 40,867 (262)

Denosumab

Reactions Weekly, 2016
  +6 more sources

Denosumab

Reactions Weekly, 2015
  +4 more sources

Denosumab

Reactions Weekly, 2018
  +5 more sources

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

The Lancet Diabetes and Endocrinology, 2017
H. Bone, R. Wagman, M. Brandi, Jacques P. Brown, R. Chapurlat, S. Cummings, E. Czerwiński, A. Fahrleitner-Pammer, D. Kendler, K. Lippuner, J. Reginster, C. Roux, J. Malouf, Michelle N. Bradley, N. Daizadeh, Andrea Wang, P. Dakin, N. Pannacciulli, D. Dempster, S. Papapoulos   +19 more
semanticscholar   +1 more source

Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials

Osteoporosis International
Takaomi Kobayashi, T. Morimoto, Koji Ito, Masaaki Mawatari, T. Shimazaki   +4 more
semanticscholar   +1 more source

Denosumab

Terapia, 2014
  +5 more sources

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

Lancet, The, 2015
Benjamin Z Leder, Hang Lee, Sherri-Ann M Burnett-Bowie   +2 more
exaly  

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

Lancet, The, 2013
Hang Lee, Sherri-Ann M Burnett-Bowie, Benjamin Z Leder   +2 more
exaly  

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Lancet, The, 2015
Michael Fx Gnant, Richard F Greil, Marija Balic   +2 more
exaly  

Denosumab and fracture risk in women with breast cancer

Lancet, The, 2015
Thierry Trenque
exaly   +2 more sources